Literature DB >> 18071304

Protein kinase A-mediated phosphorylation of the NF2 tumor suppressor protein merlin at serine 10 affects the actin cytoskeleton.

M Laulajainen1, T Muranen, O Carpén, M Grönholm.   

Abstract

Mutations in the neurofibromatosis 2 tumor suppressor gene (NF2) encoding merlin (moesin-ezrin-radixin like-protein) induce tumors of the nervous system. Merlin localizes to the cell membrane where it links the actin cytoskeleton to membrane proteins. Cell proliferation is regulated by merlin in many cell types, but merlin's tumor suppressor function still remains unclear. Phosphorylation has been suggested to regulate merlin's activity. The C-terminal serine 518 is phosphorylated both by p21-activated kinases (PAKs) and protein kinase A (PKA). In this work, we identify a novel PKA phosphorylation site, serine 10, in the N terminus of merlin. We show that a non-phosphorylatable form of serine 10 (S10A) affects cellular morphology. Regulation of this site also influences actin cytoskeleton organization and dynamics in vivo, as merlin S10A reduces the amount of cellular F-actin and merlin S10D stabilizes F-actin filaments. By using a wound-healing assay and live cell imaging, we demonstrate that dephosphorylation of serine 10 leads to defects in migration, possibly through altered ability of the cells to form lamellipodia. This study suggests a role for merlin in mediating PKA-induced changes of the actin cytoskeleton.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18071304     DOI: 10.1038/sj.onc.1210988

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  26 in total

Review 1.  Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.

Authors:  Steven L Carroll
Journal:  Acta Neuropathol       Date:  2011-12-11       Impact factor: 17.088

Review 2.  Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus.

Authors:  Wei Li; Jonathan Cooper; Matthias A Karajannis; Filippo G Giancotti
Journal:  EMBO Rep       Date:  2012-03       Impact factor: 8.807

3.  Multistep phosphorylation by oncogenic kinases enhances the degradation of the NF2 tumor suppressor merlin.

Authors:  Minja Laulajainen; Taru Muranen; Tuula A Nyman; Olli Carpén; Mikaela Grönholm
Journal:  Neoplasia       Date:  2011-07       Impact factor: 5.715

4.  Unfurling of the band 4.1, ezrin, radixin, moesin (FERM) domain of the merlin tumor suppressor.

Authors:  S D Yogesha; Andrew J Sharff; Marco Giovannini; Gerard Bricogne; Tina Izard
Journal:  Protein Sci       Date:  2011-11-09       Impact factor: 6.725

5.  15α-methoxypuupehenol Induces Antitumor Effects In Vitro and In Vivo against Human Glioblastoma and Breast Cancer Models.

Authors:  Tyvette S Hilliard; Gabriella Miklossy; Christopher Chock; Peibin Yue; Philip Williams; James Turkson
Journal:  Mol Cancer Ther       Date:  2017-01-09       Impact factor: 6.261

6.  FERM domain phosphoinositide binding targets merlin to the membrane and is essential for its growth-suppressive function.

Authors:  Timmy Mani; Robert F Hennigan; Lauren A Foster; Deborah G Conrady; Andrew B Herr; Wallace Ip
Journal:  Mol Cell Biol       Date:  2011-03-14       Impact factor: 4.272

7.  Akt phosphorylation of merlin enhances its binding to phosphatidylinositols and inhibits the tumor-suppressive activities of merlin.

Authors:  Masashi Okada; Yanru Wang; Sung-Wuk Jang; Xiaoling Tang; Luca M Neri; Keqiang Ye
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

Review 8.  Merlin and the ERM proteins--regulators of receptor distribution and signaling at the cell cortex.

Authors:  Andrea I McClatchey; Richard G Fehon
Journal:  Trends Cell Biol       Date:  2009-04-01       Impact factor: 20.808

Review 9.  Molecular insights into NF2/Merlin tumor suppressor function.

Authors:  Jonathan Cooper; Filippo G Giancotti
Journal:  FEBS Lett       Date:  2014-04-12       Impact factor: 4.124

Review 10.  Neurofibromatosis type 2 protein, NF2: an uncoventional cell cycle regulator.

Authors:  Sarah Beltrami; Richard Kim; Jennifer Gordon
Journal:  Anticancer Res       Date:  2013-01       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.